Company Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

Company Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

688336

CNE1000062X2

Pharmaceuticals

Analysts' Consensus

Equities

688336

CNE1000062X2

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

EPS Revisions

Annual profits - Rate of surprise

Sector Biopharmaceuticals

Business Summary

Sales per Business

Sales per region

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

EPS Revisions

Annual profits - Rate of surprise

Sector Biopharmaceuticals

SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
24.16 ^CNY	-1.39%		-1.39%	+7.33%

Apr. 25	Sunshine Guojian Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 21	Sunshine Guojian Pharmaceutical's Profit Surges Sixfold in 2023	MT

Sunshine Guojian Pharmaceutical Shanghai Co Ltd is a China-based company mainly engaged in the research and development, industrialization and commercialization of antibody drugs. Its products are mainly used to treat major diseases such as autoimmune diseases and tumors. The Companyâs product, recombinant human type II tumor necrosis factor receptor-antibody fusion protein (trade name: YISAIPU), is a fully human antibody drug used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. The Company mainly conducts its businesses in Mainland China.

Number of employees: 965

CNY in Million	2022	Weight	2023	Weight	Delta
Antibody Drugs 100.0 %	825	100.0 %	1,014	100.0 %	+22.84%

CNY in Million	2022	Weight	2023	Weight	Delta
China 99.3 %	795	97.2 %	1,007	99.3 %	+26.66%
Other Countries 0.7 %	23	2.8 %	7	0.7 %	-68.50%

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	616,785,793	81,189,015 ( 13.16 %)	0	13.16 %

Name	Equities	%	Valuation
Asia Pacific BioMed HK Ltd. 10.23 %	9,492,064	10.23 %	31 M ¥
Shanghai Haoyi Enterprise Management Consulting Center LP 4.832 %	4,481,249	4.832 %	15 M ¥
ICBC Credit Suisse Asset Management Co., Ltd. 2.307 %	2,139,775	2.307 %	7 M ¥
Orient Securities Asset Management Co. Ltd. 1.101 %	1,021,254	1.101 %	3 M ¥
Fullgoal Fund Management Co., Ltd. 1.004 %	931,275	1.004 %	3 M ¥
AXA-SPDB Investment Managers Co., Ltd. 0.9328 %	865,062	0.9328 %	3 M ¥
China Asset Management Co., Ltd. 0.9258 %	858,635	0.9258 %	3 M ¥
UBS SDIC Fund Management Co., Ltd. 0.9005 %	835,181	0.9005 %	3 M ¥
ABC-CA Fund Management Co., Ltd. 0.8415 %	780,431	0.8415 %	3 M ¥
Xiao Juan Gan 0.8158 %	756,552	0.8158 %	3 M ¥

Name	Equities	%	Valuation
3SBIO INC. 95.20 %	498,883,645	95.20 %	1 651 M ¥
Jing Lou 4.801 %	25,160,657	4.801 %	83 M ¥

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

399 Libing Road Shanghai Free Trade Zone

201203, Shanghai

http://www.3s-guojian.com

address Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd(688336)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

24.16 CNY

Average target price

32.43 CNY

Spread / Average Target

+34.23%

Consensus

Estimates Revisions

Company calendar

	1st Jan change	Capi.
SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD	+7.33%	2.06B
CSL LIMITED	+0.10%	91.42B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	41.08B
BIOGEN INC.	-9.06%	34.26B
UCB	+54.56%	25.27B
BIOMARIN PHARMACEUTICAL INC.	-16.61%	15.27B
INCYTE CORPORATION	-9.14%	12.81B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.11%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.61%	11.42B
SWEDISH ORPHAN BIOVITRUM AB	+5.32%	9.16B

Biopharmaceuticals

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Biopharmaceuticals